Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
August 12, 2020
Our organization is conducting a study for patients with primary immunodeficiency and end-stage lung disease. Patients with immunodeficiencies often develop lung complications or infections that make them ineligible for life-saving immunotherapy.
In this study, we are performing a lung transplant as well as a bone marrow transplant from the same donor.
The bone marrow transplant will provide stem cells that should generate a new immune system in the patient, which we expect will resolve the patient’s immunodeficiency and prevent organ rejection.
Initiated by the UPMC Immune Transplant and Therapy Center.
Trial Eligibility
This trial is open to pediatric and adult patients between the ages 10 and 45. For additional requirements and criteria please visit the NIH Clinical Trials website.
Study Start Date: June 20, 2013
Estimated Primary Completion Date: November 2023
Estimated Study Completion Date: November 2024
Learn more about this trial on its NIH Clinical Trials webpage or contact Shawna McIntyre, BSN, RN, at mcintyresm@upmc.edu or 412-692-5552.
Lab Team
Principal Investigators:
Paul Szabolcs, MD
John McDyer, MD
Interested in receiving specialty-specific information?
Register for UPMC Physician Resources to get emerging research, clinical updates, and free CME straight to your inbox.
